ElmediX

Focus: ElmediX is a Belgium-based biotechnology company focused on hyperthermia-based cancer treatments for advanced oncology indications. The company operates as a specialized biotech with a highly focused pipeline.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About ElmediX

AI assessmentNot Hiring

No open roles listed right now. Follow ElmediX to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Whole body hyperthermia

Advanced Cancer

N/A

Clinical Trials (1)

NCT04467593Safety Study of Whole Body Hyperthermia for Advanced Cancer

N/A

Help build intelligence for ElmediX

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on novel, non-traditional cancer treatment modality (whole body hyperthermia) with potential differentiation in crowded oncology market
European biotech base in Leuven provides access to strong academic partnerships and EU research funding networks
Early-stage company offers potential for significant career impact and responsibility as core team member

Watch Out For

Currently zero open job positions signals minimal hiring activity and limited near-term career mobility or team expansion
Extremely early-stage pipeline (only 1 active trial, phase designation unknown) creates significant clinical and commercial risk with no revenue, funded pipeline depth, or clear path to inflection
Lack of disclosed funding, employee count, and financial metrics indicates limited visibility into company stability, capitalization, or long-term viability

Generated by Claude from ElmediX's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline